CLINICAL TRIAL TO EVALUATE THE EFFICACY & SAFETY OF UNANI FORMULATION "TAB DAMWI" IN SOO-UL-QINYA (HYPO-CHROMIC ANEMIA)
Noman Khan, Farah Naaz*, Mohd. Abid and Mohd. Arshad Ansari
Hypochromic anemia due to iron deficiency is responsible for greater morbidity and mortality than any other haematologic disorder. Anaemia is a worldwide problem with the highest prevalence in developing countries. It is estimated that about 10% populations of developed countries and as much as of 25-50% in developing. National Family Health Survey discloses that 50% of Indian woman are anaemic and 20% maternal deaths is directly related to anaemia. In rural India, anemia is much more prevalent, even among men. The important etiologies may include GI blood loss due to intestinal worm infestation, NSAIDs, malignancies, multiple pregnancies, menstrual irregularities, growth spurts, etc. It is characterized by stomatitis, glossitis, swollen & inflamed gums, pallor on conjunctiva and nails, fatigue and exertional dyspnoea. The management of the disorder comprises dietary/drug supplementation containing iron in different forms. Despite availability of iron supplements, anemia is still a health challenge across the globe. The Unani drugs being safe, efficacious, easily available, cost effective and above all free from after effects of medications can play an important role in eradication of this problem if properly researched. Unani system of medicine uses holistic approach, most of the medicines employed for anemia comprise iron on one hand and having hepatoprotective/ haemopoietic activity on the other. The trial drug shows significant improvement overall in symptoms & signs and laboratory findings of the disorder as well as when compared to the standard control group. The formulation was found effective and completely safe in Soo-ul-Qinya (Hypo-Chromic Anemia).
Keywords: Anaemia, hepatoprotective/ haemopoietic.
[Full Text Article]